View Clinical Trial (Medical Research Study)
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
| City: |
|
Phoenix |
| State: |
|
Arizona |
| Zip Code: |
|
|
| Conditions: |
|
Age-related Macular Degeneration |
| Purpose: |
|
This study is conducted in 2 stages. Stage 1 is an open-label, dose-escalation assessment
of the safety of AGN-150998 administered as an intravitreal injection to patients with
exudative Age-related Macular Degeneration (AMD). Stage 2 is a randomized, double-masked,
comparison of the safety and treatment effects on retinal edema and best-corrected visual
acuity (BCVA) of AGN-150998 and ranibizumab in patients with exudative AMD. The study
objectives are (1) to identify the highest tolerated dose of AGN-150998, (2) to assess the
safety and duration of treatment effects on retinal edema and BCVA, and (3) to characterize
the systemic pharmacokinetic profile of AGN-150998.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Age-related macular degeneration
- Best-corrected visual acuity between 20/40 and 20/800
Exclusion Criteria:
- Near-sightedness of 8 diopters or more
- Uncontrolled glaucoma in the study eye
- Cataract surgery or Lasik within the last 3 months
- Any active ocular infection or inflammation
|
| NCT ID: |
|
NCT01397409 |
| Primary Contact: |
|
Study Director
Medical Director
Allergan
Allergan Inc
Email: clinicaltrials@allergan.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Phoenix, Arizona
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|